Rare Diseases Symptoms Automatic Extraction
Home
A random Abstract
Our Project
Our Team
A Prognostic Index to Identify Patients With Intrahepatic Cholangiocarcinoma Who Could Benefit From Gemcitabine Plus Cisplatin.
[cholangiocarcinoma]
Biliary
tract
cancer
is
a
heterogenous
group
.
Gemcitabine
plus
cisplatin
has
been
the
standard
chemotherapy
for
advanced
biliary
tract
cancer
,
but
there
is
lack
of
evidence
on
treatment
in
patients
with
intrahepatic
cholangiocarcinoma
(
IHC
)
.
We
analyzed
29
patients
with
only
IHC
who
received
gemcitabine
plus
cisplatin
between
June
2010
and
February
2013
.
The
median
age
was
63
years
(
range
,
40
-
78
years
)
,
and
Eastern
Cooperative
Oncology
Group
performance
status
of
all
patients
was
<
2
.
The
median
progression-free
survival
and
median
overall
survival
(
OS
)
were
4
.
3
and
7
.
3
months
,
respectively
.
Multivariate
analysis
showed
that
platelet
count
(
≤
180
×
10
per
liter
)
,
metastatic
site
of
more
than
2
,
and
albumin
level
(
≤
3
.
5
g
/
dL
)
were
independent
prognostic
factors
for
decreased
OS
.
OS
was
estimated
based
on
the
number
of
adverse
prognostic
factors
:
zero
or
1
(
good
prognostic
group
)
,
2
(
intermediate
group
)
,
or
3
(
poor
prognostic
group
)
.
The
median
OS
for
good
(
n
=
15
)
,
intermediate
(
n
=
10
)
,
and
poor
(
n
=
4
)
prognostic
group
was
10
.
5
,
6
.
1
,
and
1
.
6
months
,
respectively
(
P
<
0
.
005
)
.
Relatively
better
prognosis
of
the
good
prognosis
group
comparing
to
other
prognosis
groups
can
be
expected
from
the
prognostic
model
established
in
this
study
by
analyzing
patients
with
IHC
treated
with
gemcitabine
.
Diseases
Validation
Diseases presenting
"advanced biliary tract cancer"
symptom
cholangiocarcinoma
You can validate or delete this automatically detected symptom
Validate the Symptom
Delete the Symptom